TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Steroid Treatment After Resuscitated Out-of-Hospital Cardiac Arrest

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years~2. OHCA of presumed cardiac cause~3. Unconsciousness (GCS ≤8) upon pre-hospital randomization~4. Sustained ROSC for at least 5 minutes~5. Randomization and start of study medicine infusion within 30 minutes of sustained ROSC.~Exclusion Criteria:~1. Advanced life support termination-of-resuscitation exclusion criteria~2. Asystole as primary ECG rhythm~3. Women of childbearing capacity~4. Known therapy limitation~5. Known allergy to methylprednisolone~6. Known pre-arrest modified Rankin Scale (mRS) score of 4-5~7. Temperature upon randomization \<30° C~8. \>30 minutes to sustained ROSC.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methylprednisolone (Type: ACTIVE_COMPARATOR): A five minutes bolus infusion of 250 mg (4 mL) methylprednisolone to inhibit inflammatory and neurological damage following resuscitated out-of-hospital cardiac arrest. The infusion of methylprednisolone will be given following five minutes of sustainable ROSC in the prehospital setting.
- Isotonic saline (Type: PLACEBO_COMPARATOR): A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PK/PD Study of Gan & Lee Insulin Aspart Injection vs. US & EU NovoLog®/NovoRapid® in Healthy Males

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed and dated informed consent obtained before any trial-related activities. Trial-related activities are any procedures that would not have been done during normal management of the subject~2. Healthy male subjects~3. Age between 18 and 64 years, both inclusive~4. Body Mass Index (BMI) between 18.5 and 29.0 kg/m\^2, both inclusive~5. Fasting plasma glucose concentration \<= 5.50 mmol/L (100 mg/dL) at screening~6. Considered generally healthy upon completion of medical history, physical examination, vital signs, ECG and analysis of laboratory safety variables, as judged by the Investigator~Exclusion Criteria:~1. Known or suspected hypersensitivity to investigational medicinal products (IMPs) or related product~2. Previous participation in this trial. Participation is defined as randomized~3. Use of other investigational drugs within five half-lives for enrolment or receipt of any medicinal product in clinical development within 30 days before randomization in this trial, whichever is longer~4. History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.~5. Clinically significant abnormal values for haematology, biochemistry, coagulation, or urinalysis as judged by the Investigator~6. Increased risk of thrombosis, e.g subjects with a history of deep leg vein thrombosis or family history of deep leg vein thrombosis, as judged by the Investigator~7. A positive result in the alcohol and/or urine drug screen at the screening visit~8. Positive to the screening test for Hepatitis Bs antigen or Hepatitis C antibodies and/or a positive result to the test for HIV-1/2 antibodies or HIV-1 antigen~9. Blood donation or blood loss of m ore than 500 mL within the last 3 months

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Gan & Lee Insulin Aspart (Type: EXPERIMENTAL): 100 units/mL, 3 ml prefilled pen
- NovoRapid® Insulin Aspart (Type: ACTIVE_COMPARATOR): Product approved and marketed in the EU~FlexPen100 units/mL prefilled pen
- NovoLog® Insulin Aspart (Type: ACTIVE_COMPARATOR): Product approved and marketed in the US~FlexPen100 units/mL prefilled pen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sound Quality Comparisons With Different Hearing Aid Couplings and Venting Systems

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Mild to severe bilateral sensorineural hearing loss~* hearing must be symmetrical below 500 Hz~* must live within 30 miles of Aurora IL~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Custom earmolds, then Open domes, then Vented domes (Type: EXPERIMENTAL): Participants first fit with Audeo 90P hearing aids and custom earmolds with dynamic venting, then fit with the same hearing aids using open domes, then fit with the same hearing aids using vented domes.
- Open domes, then Vented domes, then Custom earmolds (Type: EXPERIMENTAL): Participants first fit with Audeo 90P hearing aids and open domes, then fit with the same hearing aids using vented domes, then fit with the same hearing aids using custom earmolds with dynamic venting.
- Vented domes, then Custom earmolds, then Open domes (Type: EXPERIMENTAL): Participants first fit with Audeo 90P hearing aids and vented domes, then fit with the same hearing aids using custom earmolds with dynamic venting, then fit with the same hearing aids using open domes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Insulin detemir naive~* Type 1 diabetes for at least 12 months~* HbA1c lesser than or equal to 11.0%~Exclusion Criteria:~* Significant concomitant diseases

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- insulin detemir (Type: EXPERIMENTAL): insulin detemir + insulin aspart
- NPH insulin (Type: EXPERIMENTAL): NPH insulin + insulin aspart

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent~* Male or female aged from 40 to 88 years old~* Scheduled to undergo unilateral cataract surgery~Exclusion criteria:~* Combined surgery~* Previous intraocular surgery

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 88 Years
- Healthy Volunteers: f

Study Arms:
- T2380 (Type: EXPERIMENTAL): Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.~At the beginning of surgery, 200 μL of T2380 were administrated intracamerally.
- Mydriatics and anesthetic (Type: ACTIVE_COMPARATOR): Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.~Topical Mydriatic treatments were instilled three times before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multi-site Randomized Controlled Trial Comparing Regional and General Anesthesia for Effects on Neurodevelopmental Outcome and Apnea in Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any infant scheduled for unilateral or bilateral inguinal hernia repair (with or without circumcision)~* Any infant whose gestational age is 26 weeks or more (GA = 182 days)~* Any infant whose post-menstrual age is up to 60 weeks (PMA = 426 days)~Exclusion Criteria:~* Any child older than 60 weeks post-menstrual age~* Any child born less than 26 weeks gestation~* Any contraindication to general or spinal/caudal anesthesia (for example: neuromuscular disorder or coagulopathy)~* Pre-operative ventilation immediately prior to surgery~* Congenital heart disease that has required ongoing pharmacotherapy~* Known chromosomal abnormality or any other known acquired or congenital abnormalities (apart from prematurity) which are likely to affect development~* Children where follow-up would be difficult for geographic or social reasons~* Families where English is not the primary language spoken at home~* Known neurological injury such as cystic periventricular leukomalacia (PVL), or grade 3 or 4 intra ventricular hemorrhage (ICH) (+/- post hemorrhage ventricular dilation)~* Previous exposure to volatile anesthesia or benzodiazepines as a neonate or in the third trimester in utero.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 60 Weeks
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Regional Anesthesia
- 2 (Type: ACTIVE_COMPARATOR): General Anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must have completed the double-blind phase of Study TKT024, defined as completing the Week 53 final evaluations.~* Patient, patient's parent(s), or legally authorized representative must have voluntarily signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent form after all relevant aspects of the study have been explained and discussed with the patient.~Exclusion Criteria:~* Patient has received treatment with an investigational therapy other than iduronate-2-sulfatase in Study TKT024 within the past 60 days.~* Patient is unable to comply with the protocol (e.g., due to a medical condition such as cervical cord compression or uncooperative attitude) or is unlikely to complete the study, as determined by the investigator.~* Patient has experienced an adverse reaction to study drug in Study TKT024, which contraindicates further treatment with idursulfase.~* Patient with known hypersensitivity to any of the components of idursulfase.

- Gender: MALE
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Idursulfase (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Provide signed written informed consent~* Have a diagnosis of POAG or OHT in both eyes, or one eye with POAG and the other with OHT.~* Qualifying corrected visual acuity in each eye~* Qualifying central corneal thickness in each eye~* Qualifying Day 1 IOP measurement at 3 time-points in both eyes~* Qualifying Anterior chamber angle~Exclusion Criteria:~* History of ocular surgery specifically intended to lower IOP~* Subjects who cannot safely discontinue use of ocular hypotensive medications during the wait/washout period~* Advanced glaucoma in either eye~* Any corneal abnormality or other condition interfering with or preventing reliable Goldmann applanation tonometry~* Any ocular surgery or ocular laser treatment within 180 days prior to Screening and throughout the study in either eye~* Females who are pregnant, nursing, or planning a pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug Arm: DE-117 QD (Type: EXPERIMENTAL): DE-117 Ophthalmic Solution QD (20:00) and Vehicle (8:00; no active DE-117 ingredient) QD
- Test Arm: DE-117 BID (Type: EXPERIMENTAL): DE-117 Ophthalmic Solution BID Twice daily (20:00 and 8:00)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Males age 18-50~* Normal serum testosterone, LH and FSH~* PSA \< 4.0~* Agrees not to donate blood or participate in another research study during the study~* Informed consent~* In general good health based on normal screening evaluation (consisting of a medical history, physical exam, normal sperm count, normal serum chemistry and hematology)~* Must be willing to use a reliable form of contraception during the study~Exclusion Criteria:~* Oligospermia (sperm count \< 15 million/mL after 48 hours of abstinence) and/or abnormal motility or morphology.~* Participation in a long-term male contraceptive study within the past three months~* History of testosterone or anabolic steroid abuse in the past~* Poor general health with significantly abnormal blood results~* History of or current testicular disease~* History of a bleeding disorder or need for anticoagulation~* History of sleep apnea and/or major psychiatric problems~* BMI \> 32~* Subjects with a skin condition that might interfere or be exacerbated by testosterone gel use~* Subject's with alcohol or drug use

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Acyline plus Placebo (Type: EXPERIMENTAL): Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous placebo hCG injection (inj) every other day (5 doses) for 10 days
- Acyline plus 15 IU hCG (Type: EXPERIMENTAL): Acyline 300 ug/kg (SQ) inj(s) on Day 1 plus subcutaneous 15 IU hCG injection (inj) every other day (5 doses) for 10 days
- Acyline plus 60 IU hCG (Type: EXPERIMENTAL): Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 60 IU hCG injection (inj) every other day (5 doses) for 10 days
- Acyline plus 125 IU hCG (Type: EXPERIMENTAL): Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 125 IU hCG injection (inj) every other day (5 doses) for 10 days
- Acyline plus Testosterone gel (Type: EXPERIMENTAL): Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus Testosterone gel 75 mg/day daily for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age more than or equal to 18 years at the time of signing informed consent~* Body mass index more than or equal to 30 kg/m\^2 or more than or equal to 27 kg/m\^2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease~* History of at least one self-reported unsuccessful dietary effort to lose body weight~Exclusion Criteria:~* Hemoglobin A1c more than or equal to 48 mmol/mol (6.5%) as measured by the central laboratory at screening~* A self-reported change in body weight more than 5 kg (11 lbs) within 90 days before screening irrespective of medical records

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): Participants will receive semaglutide 2.4 mg during 68-week treatment period in addition to intensive behavioural therapy.
- Semaglutide placebo (Type: PLACEBO_COMPARATOR): Participants will receive semaglutide placebo during 68-week treatment period in addition to intensive behavioural therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Change of Airway Hyperresponsiveness to Mannitol and Methacholine in Patients With Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* clinically well-controlled asthma~Exclusion Criteria:~* Smokers~* women planning a pregnancy or pregnant~* patients with any significant illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- montelukast (Type: EXPERIMENTAL): A leukotriene receptor antagonist (LTRA, montelukast) is added to a basic treatment of inhaled corticosteroids (ICS) + long-acting betamimetics (LABA) in well-controlled patients with asthma.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of the Supraspinal Opioidergic Circuit in Prefrontal TMS-Induced Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy volunteers~* no history of depression or pain~* no metal in body~* no medications that lower seizure threshold~Exclusion Criteria:~* history of depression or pain~* history of seizures or epilepsy~* metal implants in body~* medications that lower seizure threshold~* psychiatric medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Saline (Type: PLACEBO_COMPARATOR): Participants received intravenous saline immediately prior to sham and real rTMS of the left dorsolateral prefrontal cortex. The parameters of the stimulation paradigm are as follows: 10 Hz, 5 seconds on, 10 seconds off, 20 minutes, 4000 pulses).
- Naloxone (Type: ACTIVE_COMPARATOR): Participants received intravenous naloxone (0.1mg/kg) immediately prior to sham and real rTMS of the left dorsolateral prefrontal cortex. The parameters of the stimulation paradigm are as follows: 10 Hz, 5 seconds on, 10 seconds off, 20 minutes, 4000 pulses).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subjects with stable health condition as determined by past medical history, physical examination, electrocardiogram, and laboratory tests at screening.~* Patients with dysglycemia are patients with: Fasting plasma glucose \>100mg/dL (5.6 mmol/L), or HbA1c \> 5.7% and \< 10% at screening.~* Fasting plasma glucose ≤250mg/dL (13.9 mmol/L) at screening.~* If treated with antidiabetic medications (other than prohibited medications), patients must be on a stable dose for 12 weeks prior to randomization and maintain the dose until the end of the study.~* Subjects must have a body mass index (BMI) within the range of 35 - 50 kg/m2 at screening, with stable body weight (± 5 kg) within 3 months prior to screening~Key Exclusion Criteria:~* Pre-existing, clinically significant gastrointestinal, liver, cardiovascular, renal or other chronic medical condition which is considered serious or unstable, other than stable cardiovascular disease, treated hypertension, dyslipidemia or other stable chronic disorders~* Clinically significant GI disorder related to malabsorption or that may affect drug or glucose absorption or history of significant gastrointestinal surgery that could affect intestinal glucose absorption~* Enrollment in a diet, weight loss or exercise programs with the specific intent of losing weight, within 3 months prior to randomization, or clinical diagnosis of any eating disorder~* Pregnant or nursing (lactating) women, and women of child-bearing potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Part 1: LIK066 150 mg once daily (qd) (Type: EXPERIMENTAL): LIK066 150 mg qd within 15 minutes before starting lunch
- Part 1: Placebo once daily (Type: PLACEBO_COMPARATOR): Matching placebo tablets of LCZ696 150 mg within 15 minutes before starting lunch.
- Part 2: LIK066 75 mg twice daily (bid) (Type: EXPERIMENTAL): LIK066 75 mg bid before breakfast and dinner
- Part 2: LIK066 50 mg three times daily (tid) (Type: EXPERIMENTAL): LIK066 50 mg tid before all 3 meals;
- Part 2: Placebo three times daily (Type: PLACEBO_COMPARATOR): Matching placebo tablets tid before meals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete